^
Association details:
| Biomarker: | MSI-H/dMMR |
|---|---|
| Cancer: | Esophageal Cancer |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) + Imjudo (tremelimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
08/29/2023
Excerpt:
Esophageal and Esophagogastric Junction Cancers: Useful in Certain Circumstances…MSI-H/dMMR tumors…Tremelimumab and durvalumab for neoadjuvant therapy only…
Source:
Title:
Study on the combination of two immunotherapeutic agents as pre-surgical therapy or definitive treatment in patients with resectable gastric or gastroesophageal junction cancer with microsatellite instability. Studio con la combinazione di due farmaci immunoterapici come terapia prima della chirurgia o come terapia definitiva in pazienti con tumore gastrico o della giunzione gastro-esofagea operabile con instabilità dei microsatelliti.
Excerpt:
...MSI-high and dMMR status confirmed by IHC and multiplex PCR, and EBV-negative status by ISH, as determined centrally at the Co-ordinating Centre. ...
Trial ID:
